Cassava Sciences to Hold Corporate Update on November 25th

Core Viewpoint - Cassava Sciences, Inc. is set to hold a conference call and webcast to discuss developments related to its Alzheimer's disease treatment on November 25, 2024 [1][2]. Company Overview - Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas, focused on detecting and treating neurodegenerative diseases, particularly Alzheimer's disease [3]. - The company owns exclusive, worldwide rights to its investigational product candidates and related technologies, including Simufilam, without royalty obligations to any third party [4]. Product Information - Simufilam is an investigational oral small molecule drug candidate currently being evaluated in two Phase 3 clinical trials for the potential treatment of Alzheimer's disease [4].